Erasca, Inc. (NASDAQ:ERAS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Erasca, Inc. (NASDAQ:ERAS) have been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $20.6364.

A number of equities analysts have commented on ERAS shares. Wolfe Research set a $16.00 target price on shares of Erasca in a research note on Thursday, June 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a report on Thursday, June 11th. Mizuho dropped their price target on shares of Erasca from $28.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. Jefferies Financial Group restated a “buy” rating on shares of Erasca in a report on Tuesday, July 14th. Finally, HSBC set a $20.00 price target on shares of Erasca in a research report on Tuesday, July 14th.

Institutional Investors Weigh In On Erasca

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its holdings in shares of Erasca by 594.8% during the 1st quarter. AQR Capital Management LLC now owns 396,202 shares of the company’s stock worth $543,000 after purchasing an additional 339,177 shares during the period. Geode Capital Management LLC lifted its position in Erasca by 1.6% in the second quarter. Geode Capital Management LLC now owns 4,835,642 shares of the company’s stock valued at $6,143,000 after buying an additional 77,790 shares during the last quarter. Creative Planning lifted its position in Erasca by 423.3% in the second quarter. Creative Planning now owns 244,332 shares of the company’s stock valued at $310,000 after buying an additional 197,637 shares during the last quarter. New York State Common Retirement Fund lifted its position in Erasca by 39.1% in the second quarter. New York State Common Retirement Fund now owns 37,360 shares of the company’s stock valued at $47,000 after buying an additional 10,501 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Erasca by 51.6% during the second quarter. Invesco Ltd. now owns 172,226 shares of the company’s stock worth $219,000 after buying an additional 58,643 shares during the period. Hedge funds and other institutional investors own 67.78% of the company’s stock.

Erasca Price Performance

Shares of ERAS opened at $19.17 on Monday. Erasca has a 52-week low of $1.33 and a 52-week high of $24.28. The stock has a fifty day simple moving average of $14.55 and a two-hundred day simple moving average of $13.44. The company has a market capitalization of $5.96 billion, a PE ratio of -20.61 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). As a group, equities analysts anticipate that Erasca will post -0.55 earnings per share for the current fiscal year.

Erasca News Summary

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: No clear positive company-specific developments were reported in the provided articles.
• Neutral Sentiment: Multiple law firms, including Robbins Geller, Rosen, Faruqi & Faruqi, KSF, Glancy Prongay, Pomerantz, and others, issued reminders about the August 10, 2026 lead-plaintiff deadline in the existing class action. Article Title
• Neutral Sentiment: Hagens Berman said it is investigating claims tied to alleged patent-litigation exposure and patient-safety risks, reinforcing the market’s focus on legal and regulatory uncertainty around Erasca’s pipeline. Article Title
• Negative Sentiment: The class-action allegations suggest investors may have been misled about ERAS-0015’s advantages and risk profile, which can weigh on sentiment and raise concern about potential financial liabilities. Article Title

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.